TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD Insider Trading

Former CFO Eliyahu Sharon Kalif sold 106,563 shares of TEVA at $34.10 under pre-arranged 10b5-1 plan; holdings reduced -61.9%

Eliyahu Sharon Kalif, who was CFO at the time, sold 106,563 shares of TEVA at $34.10 on 2026-06-11 as part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-26, reducing his holdings from 172,184 shares to 65,621 shares. Because this transaction is scheduled rather than discretionary, it carries no signal regarding conviction or timing. Historically, his 5 prior trades at TEVA have shown mixed outcomes: the most recent sale on 2026-05-14 declined -2.8% over 30 days, while his 2025-06-12 sale declined -4.0% over 30 days but gained +14.6% over 90 days. TEVA currently trades at $33.69, down -9.8% from its 52-week high of $37.34, with the company reporting $4.0B in latest quarterly revenue and a P/E of 25.14.

CFO (then) Kalif Eliyahu Sharon sold 153,251 shares of TEVA at $35.61 under 10b5-1 plan; stock now -8.8% from 52-week high.

Kalif Eliyahu Sharon, who was CFO at the time of this transaction, executed a scheduled sale of 153,251 shares ($5.5M value) under a pre-arranged 10b5-1 trading plan adopted on 2025-11-26, reducing his holdings by 47.1%. The sale occurred at $35.61 on 2026-05-14; the stock currently trades at $34.05, down 8.8% from its 52-week high of $37.34. His prior four trades at TEVA show subsequent 90-day returns of +1.9%, +14.6%, +8.2%, and +23.0%, while his cross-ticker track record of 4 prior sells averaged 90-day return of +11.9%. Because this transaction is part of a scheduled 10b5-1 plan, it reflects commitment to a predetermined schedule rather than discretionary market timing decisions. Investors should note that Sharon is no longer the current CFO per the most recent 10-Q/10-K SOX certification.

Daniell Richard, EVP Europe Commercial at TEVA, sells 30,000 shares (35% of holdings) as stock nears 52-week highs.

Daniell Richard, EVP Europe Commercial, sold a substantial block representing more than one-third of his holdings at a time when TEVA's stock is trading near its 52-week highs. His prior selling activity over the past two months shows consistent patterns — in the 30-day windows following his earlier March sales, the stock declined, indicating well-timed exits that avoided further downside. However, over longer 90-day periods, those earlier sales preceded modest gains, suggesting his timing works on near-term windows but not intermediate horizons. The company itself remains solidly profitable with healthy revenue and earnings, so this sale does not signal financial distress; rather, it reflects a seasoned executive taking liquidity at a strong price point. This sale marks the continuation of a disciplined selling pattern rather than a sudden shift in conviction.

Officer Sabag Mark sells 144,180 TEVA shares (64% of holdings) for $5M; sixth open-market sale in 36 months with mixed timing history.

Mark Sabag, a TEVA officer, executed his sixth open-market sale in the past three years, disposing of roughly two-thirds of his remaining stake for over $5 million. His prior five sales at TEVA showed mixed results: two were well-timed exits where the stock subsequently declined, while three were followed by meaningful gains, suggesting he has historically exited at suboptimal moments more often than not. TEVA itself remains a profitable company with growing revenue and solid quarterly results, but the stock has rallied sharply in recent weeks and now trades near its 52-week high—a position where executives historically take profits more readily. Sabag's sustained pattern of selling, combined with the price level at which this sale occurred, reflects opportunistic liquidation rather than distress or major operational concern, but the repeated exits over three years underscore a pattern of persistent reduction in his personal exposure to the company.

Sabag Mark sells 62.1K TEVA shares at $30.14; stock down 18.8% from 52-week high, cross-ticker sells average +5.7% 30d return.

Sabag Mark sold 62,102 shares of TEVA at $30.14 on 2026-03-17, reducing his holdings by 21.6% from 287,042 to 224,940 shares. The stock currently trades at $29.44, having declined 18.8% from its 52-week high of $36.25 and fallen 14.4% in the past 30 days. Across his cross-ticker track record, his prior sells averaged a 30-day return of +5.7% and 90-day return of +8.2%, suggesting historical underperformance of this transaction's timing; however, his prior trades at TEVA specifically show mixed timing outcomes, with two December 2025 sales generating 13%+ 30-day returns but only 1 of 5 prior TEVA sales well-timed at the 90-day horizon. TEVA's valuation metrics show a P/E of 9.00 and latest-quarter revenue of $4,480,000,000.00 with net income of $433,000,000.00, supporting a stable financial foundation despite recent share price volatility.

EVP Richard sells 91,345 TEVA shares for $2,983,516.68 at $32.66 avg; holds 85.8K post-sale

Daniell Richard (EVP, Europe Commercial) executed three separate sales totaling 91,345 shares for $2,983,516.68 on 2026-03-04, reducing his holdings by -51.6% from 177.1K to 85.8K shares. The blended average transaction price of $32.66 sits above the current price of $31.05 and near the 52-week high of $36.25 (within -14.3% of peak). Richard's same-ticker history at TEVA shows two recent prior sales on 2026-03-03 (outcomes not yet measurable) and mixed timing on earlier TEVA trades: his 2025-03-05 paired sales both showed -13.3% 30-day returns but +8.0% 90-day returns, indicating the stock recovered after his sales. His cross-ticker track record of 14 prior sells reflects a 9.09% well-timed rate with +11.1% average 90-day returns, suggesting his prior sales have not consistently preceded declines. The fundamental backdrop shows TEVA with a low P/E of 9.50, positive annual revenue growth of +4.3%, and $433.0M net income, creating a valuation context that does not obviously signal distress.

TEVA EVP Daniell Richard sells 128,985 shares at $32.36 for $4,173,941.71; reduces stake by 51.2%.

Daniell Richard, EVP Europe Commercial at TEVA, executed two separate sales on 2026-03-03, offloading 128,985 shares (129.0K shares) at a blended average of $32.36 for total proceeds of $4,173,941.71 ($4.2M), reducing his post-transaction holdings from 252,112 shares to 123,127 shares—a 51.2% reduction in stake. The transaction occurred at $32.36, which was near the 52-week high of $36.25; the current price is $31.75, down 12.4% from the 52-week high. Across his cross-ticker track record of 15 prior open-market sells, the insider's average 90-day return was +11.1%, with a 90-day well-timed rate of 9.09%; his prior same-ticker sales at TEVA show mixed results, with one 2025 sale producing a -13.3% 30-day return, though his most recent 2025-12-09 sale posted +13.4% at the 30-day mark. The stock's P/E of 9.71, quarterly revenue of $4,480,000,000, and net income of $433,000,000 suggest a lower-valuation industrial/pharma profile; the substantial 51% stake reduction warrants investor attention to understand whether this represents a structural shift in the executive's equity commitment.

CFO Kalif Eliyahu Sharon sells 345,810 shares of TEVA at $33.64 for $11.6M, reducing holdings by 85.7%

Kalif Eliyahu Sharon, TEVA's Chief Financial Officer, executed a substantial open-market sale of 345,810 shares at $33.64 on 2026-02-26, reducing his holdings from 403,288 to 57,478 shares—an 85.7% reduction in position size. The $11,634,708.29 transaction occurs at a price 6.8% below the 52-week high of $36.25 and represents his third consecutive sell in the past twelve months at TEVA; across his same-ticker history, his prior two sales yielded 90-day returns of +14.6% and +8.2%, indicating he has not consistently sold ahead of declines at this stock. The stock's 90-day gain of +25.6% and trailing P/E of 10.33 suggest a relatively low valuation relative to recent momentum, though his track record across all tickers shows a 0.00% well-timed sell rate at the 90-day mark (avg 90-day return +15.3% after his prior sells), meaning his previous sales occurred before subsequent price appreciation rather than before declines.

TEVA CEO Francis sold 447,778 shares for $15.3M under pre-arranged 10b5-1 plan; holdings reduced to 605.8K

Francis Richard D, President and CEO of TEVA Pharmaceutical Industries, executed 2 separate sales totaling 447,778 shares for $15,324,799.05 at a blended average price of $34.22 on 2026-02-15. This represents a -42.5% reduction in his holdings, from 1,053,549 shares pre-transaction to 605,771 shares post-transaction. The transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-14, meaning the sales were scheduled rather than discretionary. While the magnitude of the position reduction is substantial, the scheduled nature of the plan removes any ability to infer timing-driven intent from the filing itself.

Director MIGNONE ROBERTO sells 77.4K TEVA shares at $30.24; stock at 52-week high, up 22.1% in 30 days.

MIGNONE ROBERTO sold 77,400 shares at $30.24 on 2025-12-16, reducing holdings by 17.4% from 445,000 to 367,600 shares, with total proceeds of $2,340,645.66. The transaction occurred at the 52-week high of $30.32 and follows a 22.1% surge over 30 days and 65.2% gain over 90 days, setting up a timing test against his pattern. At the same ticker, his prior 2 measurable 90-day outcomes were split (50% well-timed): a -26.2% outcome on 2024-12-20 and +6.1% on 2024-06-18, neither establishing a consistent signal at TEVA. His cross-ticker track record shows only 50.0% of sells were well-timed (negative 90d return), with an average 90d return of -10.0% after sells—meaning his sells historically preceded modest declines, though this insider has not demonstrated strong timing precision overall. The company's elevated P/E of 48.90 and full-year unprofitability warrant scrutiny in the context of recent strong stock momentum.